- 13 次围观
产品图片
货号/SKU
NR-749
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、1
产品描述信息
NR-749??Vaccinia virus, Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (ascites) (Similar to VMC-5) (Monoclonal Antibodies)|Vaccinia virus|Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (ascites) (Similar to VMC-5) |-20°C|GH Cohen, RJ EisenbergAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Vaccinia Virus (WR) L1R Protein, Residues 1 to 185 (ascites, Mouse) (Similar to VMC-5), NR-749."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Mouse monoclonal antibody to a recombinant form of the L1R protein [L1R(185t); residues 1 to 185, C-terminal histidine-tagged] of the Western Reserve (WR) strain of vaccinia virus was purified from mouse ascites by protein A affinity chromatography. The mouse B cell hybridoma was generated by the fusion of SP2/0 myeloma cells with immunized BALB/c splenocytes. NR-749 was purified from the same hybridoma as VMC-5. The specificity of VMC-5 was determined by reactivity to L1R(185t) by ELISA and confirmed by Western blot analysis under reducing and non-reducing conditions. The reactivity pattern in ELISA assays using overlapping peptides spanning residues 1 to 185 of L1R indicates that VMC-5 recognizes an epitope within amino acids 118 to 128. VMC-5 neutralizes the infectivity of the intracellular mature virus (IMV) form of vaccinia virus in BS-C-1 cells using an IMV plaque reduction assay.
The purified monoclonal antibody is provided frozen at 1 mg per vial in phosphate buffered saline (pH 7.3) containing 0.05% sodium azide.
Mouse monoclonal antibody to a recombinant form of the L1R protein [L1R(185t); residues 1 to 185, C-terminal histidine-tagged] of the Western Reserve (WR) strain of vaccinia virus was purified from mouse ascites by protein A affinity chromatography. The mouse B cell hybridoma was generated by the fusion of SP2/0 myeloma cells with immunized BALB/c splenocytes. NR-749 was purified from the same hybridoma as VMC-5. The specificity of VMC-5 was determined by reactivity to L1R(185t) by ELISA and confirmed by Western blot analysis under reducing and non-reducing conditions. The reactivity pattern in ELISA assays using overlapping peptides spanning residues 1 to 185 of L1R indicates that VMC-5 recognizes an epitope within amino acids 118 to 128. VMC-5 neutralizes the infectivity of the intracellular mature virus (IMV) form of vaccinia virus in BS-C-1 cells using an IMV plaque reduction assay.
The purified monoclonal antibody is provided frozen at 1 mg per vial in phosphate buffered saline (pH 7.3) containing 0.05% sodium azide.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.在这一限制下订单将在发货前发送到NIAID批准. L1R蛋白的重组形式的小鼠单克隆抗体[L1R(185t);通过蛋白质A亲和层析从小鼠腹水纯化西方储备(WR)痘苗病毒菌株的残基1至185,C-末端组氨酸标记物.通过具有免疫BALB / C脾细胞的SP2 / 0骨髓瘤细胞的融合产生小鼠B细胞杂交瘤.从与VMC-5相同的杂交瘤纯化NR-749. VMC-5的特异性通过ELISA的反应性确定,并通过在还原和非还原条件下通过Western印迹分析证实.使用重叠肽的ELISA测定中的反应性模式,跨越L1R的残基1-185表示VMC-5识别氨基酸118-128中的表位.VMC-5中和细胞内成熟病毒(IMV)的疫苗病毒形式的感染性使用IMV斑块还原测定的BS-C-1细胞. 纯化的单克隆抗体在含有0.05%叠氮化钠的磷酸盐缓冲盐水(pH7.3)中为每小时1mg的冷冻.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2021-12-02
2024-06-22
2022-03-31
2022-04-01
2023-11-14
2021-12-21
2022-04-01
2022-04-01
2021-12-21
2023-10-21
2021-12-21
2022-06-17
2022-04-01
2024-08-16